<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00428116</url>
  </required_header>
  <id_info>
    <org_study_id>30201-D</org_study_id>
    <secondary_id>R01HD023412</secondary_id>
    <nct_id>NCT00428116</nct_id>
  </id_info>
  <brief_title>Optimizing Pediatric HIV-1 Treatment, Nairobi, Kenya</brief_title>
  <official_title>Optimizing Pediatric HIV-1 Treatment, Nairobi, Kenya (0-4.5 Month Randomized Controlled Trial)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Washington</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Fred Hutchinson Cancer Research Center</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>University of Nairobi</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>National Institutes of Health (NIH)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Washington</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Given the high mortality associated with infant HIV-1 and the fact that surrogate markers are
      poorly predictive of mortality risk,empiric highly active antiretroviral therapy (HAART)
      initiation is started in infants younger than 12 months. A problem with this approach is that
      it obligates infants to life-long therapy, which may be associated with cumulative drug
      toxicity, poor adherence, and treatment failure. Early HAART for prevention of mortality
      during the first 2 years of life has potential to salvage immune function and alter viral
      set-point, allowing withdrawal of therapy, perhaps for several years, until subsequent CD4%
      decline requires it. This untested approach is attractive because it combines the survival
      benefits of early pediatric HAART therapy with the benefits of antiretroviral deferral.

      One hundred and fifty infants who initiated HAART at &lt;13 months of age will be treated with
      HAART regimen for 24 months after which those who have immune reconstitution and adequate
      growth (~100) will be randomized to continued versus deferred therapy. Clinical outcomes,
      growth, and toxicity will be compared in these children to determine if interruption is a
      safe and beneficial strategy. Follow-up in this studies will be closely monitored by an
      external Data Safety and Monitoring Board (DSMB).
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Hypothesis: Deferring antiretroviral therapy in infants who have immune reconstitution and
      adequate growth following early therapy of primary infection (initiated HAART during primary
      infection at less than 13 months of age) will not compromise clinical status or growth and
      may spare antiretroviral toxicity.

      Specific Aim/Primary Objective: To compare growth and morbidity in infants (who initiated
      HAART during primary infection at less than or equal to 13 months of age with subsequently
      normalized CD4% and growth following 24 months of HAART) randomized to deferred versus
      continuous therapy and followed for an additional 18 months.

      Secondary Aim/Secondary Objective: To determine predictors of non-progression of HIV among
      the infants, including: age, adherence, HIV-1 specific immune responses, baseline HIV-1 RNA,
      CD4 percent and immune activation.

      Design: Randomized clinical trial involving HIV-1 treatment of infants (&lt;13 months old) for
      24 months, followed by randomization and 18 months follow-up of children randomized to
      continued versus deferred treatment. This trial is unblinded.

      Population: HIV-1 infected infants (&lt;13 months) newly initiating HAART and HIV-1 infected
      infants already receiving HAART who initiated HAART at age &lt;13 months will be enrolled. After
      24 months of treatment follow-up, children with CD4% &gt; 25% and normalized growth will be
      retained in the study and randomized.

      Sample size: 150 infants will be enrolled of which 100 are expected to be eligible for
      randomization (50 in each arm).

      Treatment: All infants will be treated with HAART according to WHO and Kenyan national
      guidelines. The specific regimens that will be used as a part of this study are:

      First line regimen

        -  AZT/3TC/NVP (zidovudine/lamivudine/nevirapine)

        -  d4T/3TC/NVP (stavudine/lamivudine/nevirapine)

        -  AZT/3TC/ABC (zidovudine/lamivudine/abacavir)

        -  d4T/3TC/ABC (stavudine/lamivudine/abacavir)

        -  ABC/3TC/NVP (abacavir/lamivudine/nevirapine)

      Second line regimen - ddI/ABC/LPV/r (didanosine/abacavir/lopinavir-ritonavir (Kaletra))

      For infants with prior exposure to nevirapine as part of PMTCT:

      First line regimen

      - AZT/3TC/LPV/r (zidovudine/lamivudine/lopinavir-ritonavir (kaletra))
    </textblock>
  </detailed_description>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    DSMB recommended termination because TI was safe but not durable.
  </why_stopped>
  <start_date>September 2007</start_date>
  <completion_date type="Actual">December 2014</completion_date>
  <primary_completion_date type="Actual">July 2013</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Growth at 18 Months Post-randomization</measure>
    <time_frame>18 months of post-randomization follow-up</time_frame>
    <description>Weight and height will be transformed to the weight-for-age Z-score (i.e., WAZ) and height-for-age Z-score (i.e., HAZ) using World Health Organization Child Growth Standards, taking into account the infant's age and gender.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Morbidity</measure>
    <time_frame>18 months post-randomization</time_frame>
    <description>severe adverse events including death, pneumonia, diarrhea, and other adverse events</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">140</enrollment>
  <condition>HIV Infections</condition>
  <arm_group>
    <arm_group_label>Interrupted HAART</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>After 24 months of treatment with HAART, half the eligible infants will be randomized to interrupted treatment and followed for 18 months.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Continued HAART</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>After 24 months of treatment with HAART, half the eligible infants will be randomized to continued treatment with HAART for 18 months.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>HAART</intervention_name>
    <description>Combination first line antiretrovirals as previously described.</description>
    <arm_group_label>Continued HAART</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

        A. Infants newly initiating HAART

          -  Less than 13 months of age

          -  HIV-1 DNA detection with confirmation (positive on two HIV-1 DNA filter paper tests)

          -  Caregiver of infant plans to reside in Nairobi for at least 3 years (reported by
             caregiver)

          -  Caregiver is able to provide sufficient location information

        B. Infants already receiving HAART

          -  Initiated HAART at &lt;13 months of age

          -  Records confirming HIV positive status

          -  Documentation of CD4% and weight prior to HAART initiation

          -  Must be on 1st line drug regimen

        Eligibility for randomization:

          -  Completed 24 months of treatment with HAART

          -  Normalized growth: weight for height z-score (WHZ) &gt; -0.5; Child's weight must be
             above the 5th weight-for-age percentile and the weight curve must not be flat or
             falling (i.e. cross 2 major percentile lines or more over the past 3 months)

          -  CD4% &gt; 25

          -  Children who recently initiated or who require anti-tuberculosis treatment at the time
             of randomization will be ineligible for randomization.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>54 Months</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Dalton Wamalwa, MMed, MPH</last_name>
    <role>Principal Investigator</role>
    <affiliation>Department of Paediatrics and Child Health, Kenyatta National Hospital, University of Nairobi</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Grace C John-Stewart, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Washington</affiliation>
  </overall_official>
  <removed_countries>
    <country>Kenya</country>
  </removed_countries>
  <results_reference>
    <citation>Wamalwa D, Benki-Nugent S, Langat A, Tapia K, Ngugi E, Moraa H, Maleche-Obimbo E, Otieno V, Inwani I, Richardson BA, Chohan B, Overbaugh J, John-Stewart GC. Treatment interruption after 2-year antiretroviral treatment initiated during acute/early HIV in infancy. AIDS. 2016 Sep 24;30(15):2303-13. doi: 10.1097/QAD.0000000000001158.</citation>
    <PMID>27177316</PMID>
  </results_reference>
  <results_reference>
    <citation>Njuguna IN, Wagner AD, Cranmer LM, Otieno VO, Onyango JA, Chebet DJ, Okinyi HM, Benki-Nugent S, Maleche-Obimbo E, Slyker JA, John-Stewart GC, Wamalwa DC. Hospitalized Children Reveal Health Systems Gaps in the Mother-Child HIV Care Cascade in Kenya. AIDS Patient Care STDS. 2016 Mar;30(3):119-24. doi: 10.1089/apc.2015.0239.</citation>
    <PMID>27308805</PMID>
  </results_reference>
  <results_reference>
    <citation>Sridharan G, Wamalwa D, John-Stewart G, Tapia K, Langat A, Moraa Okinyi H, Adhiambo J, Chebet D, Maleche-Obimbo E, Karr CJ, Benki-Nugent S. High Viremia and Wasting Before Antiretroviral Therapy Are Associated With Pneumonia in Early-Treated HIV-Infected Kenyan Infants. J Pediatric Infect Dis Soc. 2017 Sep 1;6(3):245-252. doi: 10.1093/jpids/piw038.</citation>
    <PMID>27481854</PMID>
  </results_reference>
  <results_reference>
    <citation>Ásbjörnsdóttir KH, Hughes JP, Wamalwa D, Langat A, Slyker JA, Okinyi HM, Overbaugh J, Benki-Nugent S, Tapia K, Maleche-Obimbo E, Rowhani-Rahbar A, John-Stewart G. Differences in virologic and immunologic response to antiretroviral therapy among HIV-1-infected infants and children. AIDS. 2016 Nov 28;30(18):2835-2843.</citation>
    <PMID>27603293</PMID>
  </results_reference>
  <results_reference>
    <citation>Wagner A, Slyker J, Langat A, Inwani I, Adhiambo J, Benki-Nugent S, Tapia K, Njuguna I, Wamalwa D, John-Stewart G. High mortality in HIV-infected children diagnosed in hospital underscores need for faster diagnostic turnaround time in prevention of mother-to-child transmission of HIV (PMTCT) programs. BMC Pediatr. 2015 Feb 15;15:10. doi: 10.1186/s12887-015-0325-8.</citation>
    <PMID>25886564</PMID>
  </results_reference>
  <results_reference>
    <citation>Benki-Nugent S, Eshelman C, Wamalwa D, Langat A, Tapia K, Okinyi HM, John-Stewart G. Correlates of age at attainment of developmental milestones in HIV-infected infants receiving early antiretroviral therapy. Pediatr Infect Dis J. 2015 Jan;34(1):55-61. doi: 10.1097/INF.0000000000000526. Erratum in: Pediatr Infect Dis J. 2015 Aug;34(8):892.</citation>
    <PMID>25144793</PMID>
  </results_reference>
  <results_reference>
    <citation>Slyker JA, Casper C, Tapia K, Richardson B, Bunts L, Huang ML, Wamalwa D, Benki-Nugent S, John-Stewart G. Accelerated suppression of primary Epstein-Barr virus infection in HIV-infected infants initiating lopinavir/ritonavir-based versus nevirapine-based combination antiretroviral therapy. Clin Infect Dis. 2014 May;58(9):1333-7. doi: 10.1093/cid/ciu088. Epub 2014 Feb 18.</citation>
    <PMID>24550373</PMID>
  </results_reference>
  <results_reference>
    <citation>Langat A, Benki-Nugent S, Wamalwa D, Tapia K, Ngugi E, Diener L, Richardson BA, Melvin A, John-Stewart GC. Lipid changes in Kenyan HIV-1-infected infants initiating highly active antiretroviral therapy by 1 year of age. Pediatr Infect Dis J. 2013 Jul;32(7):e298-304. doi: 10.1097/INF.0b013e31828afb2a.</citation>
    <PMID>23385950</PMID>
  </results_reference>
  <verification_date>May 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>January 22, 2007</study_first_submitted>
  <study_first_submitted_qc>January 26, 2007</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 29, 2007</study_first_posted>
  <results_first_submitted>June 8, 2015</results_first_submitted>
  <results_first_submitted_qc>July 24, 2015</results_first_submitted_qc>
  <results_first_posted type="Estimate">August 20, 2015</results_first_posted>
  <last_update_submitted>May 1, 2017</last_update_submitted>
  <last_update_submitted_qc>May 1, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">May 3, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of Washington</investigator_affiliation>
    <investigator_full_name>Grace John-Stewart</investigator_full_name>
    <investigator_title>Professor</investigator_title>
  </responsible_party>
  <keyword>HIV-1</keyword>
  <keyword>Pediatric</keyword>
  <keyword>HAART</keyword>
  <keyword>Treatment Naive</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>HIV Infections</mesh_term>
  </condition_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Infants were identified from Nairobi City Council clinics, the Kenyatta National Hospital (KNH) wards, and the HIV treatment clinic. Recruitment occurred from 2007-2009.</recruitment_details>
      <pre_assignment_details>Of 140 infants enrolled, 37 infants died, 11 were lost, and 7 were withdrawn. Of 75 infants who completed 2 years ART pre-randomization, 33 were ineligible for randomization and 42 were randomized.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Continued HAART</title>
          <description>After 24 months of HAART, infants were continued on HAART.</description>
        </group>
        <group group_id="P2">
          <title>Interrupted HAART</title>
          <description>After 24 months of treatment with HAART, half the eligible infants will be randomized to interrupted treatment and followed for 18 months.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="21"/>
                <participants group_id="P2" count="21"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="18"/>
                <participants group_id="P2" count="21"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Death</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>following 24 months of HAART</population>
      <group_list>
        <group group_id="B1">
          <title>Continued HAART</title>
          <description>After 24 months of treatment with HAART, half the eligible infants will be randomized to continued treatment with HAART for 18 months.</description>
        </group>
        <group group_id="B2">
          <title>Interrupted HAART</title>
          <description>After 24 months of treatment with HAART, half the eligible infants will be randomized to interrupted treatment and followed for 18 months.</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="21"/>
            <count group_id="B2" value="21"/>
            <count group_id="B3" value="42"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>&lt;=18 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="21"/>
                    <measurement group_id="B2" value="21"/>
                    <measurement group_id="B3" value="42"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Between 18 and 65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt;=65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>months</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="29" lower_limit="28.8" upper_limit="33.8"/>
                    <measurement group_id="B2" value="30.0" lower_limit="29.3" upper_limit="34.9"/>
                    <measurement group_id="B3" value="30.0" lower_limit="28.9" upper_limit="34.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="15"/>
                    <measurement group_id="B2" value="8"/>
                    <measurement group_id="B3" value="23"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="6"/>
                    <measurement group_id="B2" value="13"/>
                    <measurement group_id="B3" value="19"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Kenya</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="21"/>
                    <measurement group_id="B2" value="21"/>
                    <measurement group_id="B3" value="42"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>CD4%</title>
          <units>percent</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="33" lower_limit="30" upper_limit="40"/>
                    <measurement group_id="B2" value="34" lower_limit="32" upper_limit="38"/>
                    <measurement group_id="B3" value="33" lower_limit="30" upper_limit="39"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Log10 HIV RNA level</title>
          <units>copies/ml</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="2.18" lower_limit="2.18" upper_limit="2.64"/>
                    <measurement group_id="B2" value="2.18" lower_limit="2.18" upper_limit="2.71"/>
                    <measurement group_id="B3" value="2.18" lower_limit="2.18" upper_limit="2.71"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Growth at 18 Months Post-randomization</title>
        <description>Weight and height will be transformed to the weight-for-age Z-score (i.e., WAZ) and height-for-age Z-score (i.e., HAZ) using World Health Organization Child Growth Standards, taking into account the infant's age and gender.</description>
        <time_frame>18 months of post-randomization follow-up</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Continued HAART</title>
            <description>After 24 months of treatment with HAART, half the eligible infants will be randomized to continued treatment with HAART for 18 months.</description>
          </group>
          <group group_id="O2">
            <title>Interrupted HAART</title>
            <description>After 24 months of treatment with HAART, half the eligible infants will be randomized to interrupted treatment and followed for 18 months.</description>
          </group>
        </group_list>
        <measure>
          <title>Growth at 18 Months Post-randomization</title>
          <description>Weight and height will be transformed to the weight-for-age Z-score (i.e., WAZ) and height-for-age Z-score (i.e., HAZ) using World Health Organization Child Growth Standards, taking into account the infant's age and gender.</description>
          <units>z-score</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="21"/>
                <count group_id="O2" value="21"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>WAZ (z-score)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.57" lower_limit="-0.88" upper_limit="-0.28"/>
                    <measurement group_id="O2" value="-0.17" lower_limit="-0.56" upper_limit="0.37"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>HAZ (z-score)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.04" lower_limit="-1.58" upper_limit="-0.59"/>
                    <measurement group_id="O2" value="-0.78" lower_limit="-1.62" upper_limit="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>WAZ-score comparison at 18 months</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.15</p_value>
            <method>Wilcoxon (Mann-Whitney)</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>HAZ score at 18 months</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.45</p_value>
            <method>Wilcoxon (Mann-Whitney)</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Morbidity</title>
        <description>severe adverse events including death, pneumonia, diarrhea, and other adverse events</description>
        <time_frame>18 months post-randomization</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Continue HAART</title>
            <description>After 24 months of treatment with HAART, half the eligible infants will be randomized to continued treatment with HAART for 18 months.</description>
          </group>
          <group group_id="O2">
            <title>Interrupted HAART</title>
            <description>After 24 months of treatment with HAART, half the eligible infants will be randomized to interrupted treatment and followed for 18 months.</description>
          </group>
        </group_list>
        <measure>
          <title>Morbidity</title>
          <description>severe adverse events including death, pneumonia, diarrhea, and other adverse events</description>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="21"/>
                <count group_id="O2" value="21"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Severe adverse events</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Pneumonia</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4"/>
                    <measurement group_id="O2" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Diarrhea</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7"/>
                    <measurement group_id="O2" value="12"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Death</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>SAEs</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.39</p_value>
            <method>log rank or Cox regression</method>
            <method_desc>incidence with Cox regression utilized Anderson-Gill method to handle recurrent events</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Pneumonia</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.60</p_value>
            <method>Cox regression Anderson Gill</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Pneumonia</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.60</p_value>
            <method>Regression, Cox</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Diarrhea</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.77</p_value>
            <method>Regression, Cox</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Death</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.29</p_value>
            <method>Log Rank</method>
          </analysis>
        </analysis_list>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>18 months post-randomization</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Continued HAART</title>
          <description>After 24 months of treatment with HAART, half the eligible infants will be randomized to continued treatment with HAART for 18 months.</description>
        </group>
        <group group_id="E2">
          <title>Interrupted HAART</title>
          <description>After 24 months of treatment with HAART, half the eligible infants will be randomized to interrupted treatment and followed for 18 months.</description>
        </group>
      </group_list>
      <serious_events>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="21"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="21"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Hepatobiliary disorders</title>
            <event_list>
              <event>
                <sub_title>Hepatotoxicity</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="21"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="21"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Death</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="21"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="21"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Cellulitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="21"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="21" subjects_at_risk="21"/>
                <counts group_id="E2" subjects_affected="21" subjects_at_risk="21"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Lymphadenopathy</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="21"/>
                <counts group_id="E2" subjects_affected="14" subjects_at_risk="21"/>
              </event>
              <event>
                <sub_title>Anemia</sub_title>
                <counts group_id="E1" subjects_affected="12" subjects_at_risk="21"/>
                <counts group_id="E2" subjects_affected="16" subjects_at_risk="21"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Diarrhea</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="21"/>
                <counts group_id="E2" subjects_affected="12" subjects_at_risk="21"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>High cholesterol</sub_title>
                <counts group_id="E1" subjects_affected="10" subjects_at_risk="21"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="21"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Upper respiratory infection</sub_title>
                <counts group_id="E1" subjects_affected="21" subjects_at_risk="21"/>
                <counts group_id="E2" subjects_affected="20" subjects_at_risk="21"/>
              </event>
              <event>
                <sub_title>Pneumonia</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="21"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="21"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Rash</sub_title>
                <counts group_id="E1" subjects_affected="11" subjects_at_risk="21"/>
                <counts group_id="E2" subjects_affected="11" subjects_at_risk="21"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Grace John-Stewart</name_or_title>
      <organization>University of Washington</organization>
      <phone>206 543 4278</phone>
      <email>gjohn@uw.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

